We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KWR:NYSEQuaker Houghton Analysis

Data as of 2026-04-13 - not real-time

$127.43

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Quaker Chemical (KWR) is trading around $127, which sits above the 20‑day SMA but below the 50‑day SMA, indicating a neutral price stance. The MACD histogram is positive and the RSI hovers near the mid‑range, suggesting limited upside momentum while the 40% 30‑day volatility and beta above 1.2 point to heightened price swings. Earnings are currently a mixed bag – the trailing EPS is negative, yet forward EPS forecasts jump to over $9, translating to a forward PE of roughly 13.7 and a dividend yield of 1.6% with a modest 35% payout ratio. A discounted cash‑flow model values the stock near $48, implying the market price may be stretched, though the analyst consensus still leans bullish with a "buy" rating.
Fundamentally, the company posted $1.9 B in revenue with 5.5% growth, a solid gross margin of 36%, but a thin operating margin and a marginally negative profit margin, while free cash flow remains healthy at $91 M and debt levels are moderate. The specialty chemicals sector faces medium regulatory scrutiny and the firm’s exposure to APAC EV‑fluid markets could provide a growth catalyst, but the current valuation gap and volatility suggest caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near resistance with neutral technical bias
  • Recent earnings miss reflected in negative trailing EPS
  • Stable dividend yield providing modest income

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong forward earnings outlook and forward PE around 13.7
  • Revenue growth and expanding exposure to APAC EV‑fluid market
  • Sustainable dividend payout supported by free cash flow

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Current market price significantly above DCF fair value
  • High volatility and beta indicating price sensitivity
  • Moderate debt levels but thin profit margins limiting upside

Key Metrics & Analysis

Financial Health

Revenue Growth5.50%
Profit Margin-0.13%
P/E Ratio13.7
ROE-0.18%
ROA4.47%
Debt/Equity65.81
P/B Ratio1.6
Op. Cash Flow$136.5M
Free Cash Flow$91.1M

Technical Analysis

TrendNeutral
RSI47.5
Support$112.18
Resistance$131.35
MA 20$123.02
MA 50$142.45
MA 200$137.07
MACDBullish
VolumeStable
Fear & Greed Index87.29

Valuation

Fair Value$47.99
Target Price$176.00
Upside/Downside38.12%
GradeOvervalued
TypeBlend
Dividend Yield1.60%

Risk Assessment

Beta1.25
Volatility40.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.